| Literature DB >> 32863859 |
Mengjie Rui1, Hui Pang1, Wei Ji1, Siqi Wang1, Xuefei Yu1, Lilong Wang1, Chunlai Feng1.
Abstract
BACKGROUND: Due to the lack of enough interaction data among compositions, targets and diseases, it is difficult to construct a complete network of Traditional Chinese Medicine (TCM) that comprehensively reflects active compositions and their synergistic network in terms of specific diseases. Therefore, mapping of the full spectrum of interaction between compounds and their targets is of central importance when we use network pharmacology approach to explore the therapeutic potential of the TCM.Entities:
Keywords: Canonical correlation analysis; Compound-target correlation space based interaction prediction model; Interaction prediction; Network pharmacology; Simple inference model; Traditional Chinese medicine
Year: 2020 PMID: 32863859 PMCID: PMC7448979 DOI: 10.1186/s13020-020-00369-z
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Simple inference model (SIM)
Fig. 2Compound-target correlation space based interaction prediction model (CTCS-IPM)
The predictive performance of compounds/diseases centered SIM
| Inferred interactions (Times) | Inferred basis (Known interactions) | Consistent with test set | Inferred interactions (Times) | Inferred basis (Known interactions) | Consistent with test set |
|---|---|---|---|---|---|
| C10-T8 (1) | C10-D2-T8 | Yes | D12-T13 (3) | D12-C18-T13 | Yes |
| C17-T8 (1) | C17-D2-T8 | Yes | D12-T13 (3) | D12-C17-T13 | Yes |
| C18-T8 (1) | C18-D2-T8 | Yes | D12-T13 (3) | D12-C29-T13 | Yes |
| C29-T8 (1) | C29-D2-T8 | Yes | D2-T8 (5) | D2-C29-T8 | Yes |
| C40-T8 (1) | C40-D2-T8 | Yes | D2-T8 (5) | D2-C17-T8 | Yes |
| C17-T13 (1) | C17-D12-T13 | Yes | D2-T8 (5) | D2-C10-T8 | Yes |
| C18-T13 (1) | C18-D12-T13 | Yes | D2-T8 (5) | D2-C18-T8 | Yes |
| C29-T13 (1) | C29-D12-T13 | Yes | D2-T8 (5) | D2-C40-T8 | Yes |
| D12-T8 (3) | D12-C18-T8 | New | D2-T13 (3) | D2-C17-T13 | New |
| D12-T8 (3) | D12-C17-T8 | New | D2-T13 (3) | D2-C29-T13 | New |
| D12-T8 (3) | D12-C29-T8 | New | D2-T13 (3) | D2-C18-T13 | New |
The selected compound molecular descriptors
| Molecular descriptor of compounds | Description |
|---|---|
| BCUT_SMR_3 | Molar Refractivity BCUT (3/3) |
| b_double | Number of double bonds |
| b_max1len | Maximum single-bond chain length |
| dipole | Dipole moment |
| dipoleX | Dipole moment (X) |
| dipoleY | Dipole moment (Y) |
| E_ele | Electrostatic energy |
| E_vdw | Van der Waals energy |
| FASA+ | Fractional positive accessible surface area |
| GCUT_SLOGP_2 | LogP GCUT (2/3) |
| GCUT_SMR_0 | Molar Refractivity GCUT (0/3) |
| PEOE_RPC- | Relative negative partial charge |
| PEOE_VSA + 5 | Total positive 5 vdw surface area |
| PEOE_VSA-0 | Total negative 0 vdw surface area |
| PEOE_VSA-1 | Total negative 1 vdw surface area |
| PEOE_VSA_FPOS | Fractional positive vdw surface area |
| PEOE_VSA_FPPOS | Fractional polar positive vdw surface area |
| pmiX | Principal moment of inertia (X) |
| pmiZ | Principal moment of inertia (Z) |
| Q_VSA_FPNEG | Fractional polar negative vdw surface area |
| Q_VSA_FPPOS | Fractional polar positive vdw surface area |
| rsynth | Synthetic Feasibility |
The selected protein molecular descriptors
| Molecular descriptor of proteins | Description | Molecular descriptor of proteins | Description |
|---|---|---|---|
| AL | Dipeptide composition | TR | Dipeptide composition |
| GA | VD | ||
| GK | VF | ||
| GL | VQ | ||
| GP | VR | ||
| HA | VY | ||
| HL | DL | ||
| IA | EA | ||
| ID | EL | ||
| IL | FL | ||
| IN | M-B (1) by AA index 1 | Autocorrelation descriptors | |
| IR | M-B (12) by AA index 1 | ||
| PL | M-B (21) by AA index 1 | ||
| QL | M-B (23) by AA index 1 | ||
| SA | M-B (30) by AA index 1 | ||
| SL | M-B (1) by AA index 2 | ||
| SP | M-B (10) by AA index 2 | ||
| SR | M-B (16) by AA index 2 |
Validated performance of the CTCS-IPM
| Number | The number of pairs in training dataset | The number of pairs in test dataset | The number of predicted pairs consistent with test dataset | Recall rate (%) |
|---|---|---|---|---|
| 1 | 3145 | 358 | 330 | 92.18 |
| 2 | 3145 | 358 | 329 | 91.90 |
| 3 | 3152 | 351 | 335 | 95.44 |
| 4 | 3159 | 344 | 320 | 93.02 |
| 5 | 3157 | 346 | 327 | 94.51 |
| 6 | 3156 | 347 | 332 | 95.68 |
| 7 | 3147 | 356 | 328 | 92.13 |
| 8 | 3153 | 350 | 331 | 94.57 |
| 9 | 3155 | 348 | 324 | 93.10 |
| 10 | 3158 | 345 | 321 | 93.04 |
| average | 3153 | 350 | 328 | 93.56 |
Numbers of predicted targets of compounds without any previous target information
| Phytometabolites | Compounds | Number of predicted targets | Phytometabolites | Compounds | Number of predicted targets |
|---|---|---|---|---|---|
| Flavonoids | Alexandrin | 43 | Glycosides | ||
| Miltipolone | 1 | Eleutheroside A | |||
| Salvilenone | 2 | Ginsenoside-Rh1 | |||
| Salviolone | 9 | Gypenoside VIII | |||
| Tanshinaldehyde | 2 | Gypenoside III | |||
| Tanshinone IIB | 2 | Gypenoside XVII | |||
| Tigogenin | 43 | Phenyl methane | Dicapryl Phthalate | 14 | |
| Volatile oil | Cuparene | 3 | Hydrocarbon | Docosane | 2 |
| Terpenoids | Cyperene | 1 | Ethyl Octadecadienoate | 2 | |
| α-Gurjunene | 5 | Non-3-En-2-One | 1 | ||
| α-Muurolene | 4 | Nitrogenous | Dencichine | 1 | |
| β-Cubebene | 18 | Nonsteroidal | Stigmasterol | 43 | |
| γ-Cadinene | 3 |
Parameters of original network and expanded network
| Parameters | Values of original network | Values of expanded network |
|---|---|---|
| Number of nodes | 577 | 602 |
| Number of edges | 4574 | 5602 |
| Connected components | 9 | 1 |
| Network diameter | 8 | 3 |
| Network radius | 1 | 2 |
| Network density | 0.026 | 0.289 |
| Network heterogeneity | 2.502 | 0.880 |
| Network centralization | 0.539 | 0.731 |
| Characteristic path length | 2.963 | 1.774 |
| Avg. number of neighbors | 15.854 | 5.5 |
| Isolated nodes | 0 | 0 |
Comparison of original and expanded modules focusing on specific disease
| Original modules | Expanded modules | |||||
|---|---|---|---|---|---|---|
| Compounds | Diseases | Targets | Compounds | Diseases | Targets | |
| D1 | 8 | 14 | 316 | 27 | 22 | 348 |
| D2 | 7 | 14 | 318 | 50 | 22 | 349 |
| D3 | 5 | 14 | 315 | 27 | 22 | 347 |
| D4 | 3 | 13 | 313 | 38 | 23 | 346 |
| D5 | 8 | 14 | 317 | 27 | 22 | 349 |
| D6 | 8 | 14 | 316 | 27 | 22 | 348 |
| D7 | 9 | 14 | 317 | 28 | 23 | 349 |
| D8 | 2 | 12 | 313 | 27 | 22 | 345 |
| D9 | 5 | 12 | 315 | 27 | 22 | 347 |
| D10 | 5 | 14 | 316 | 27 | 22 | 348 |
| D11 | 6 | 14 | 316 | 28 | 23 | 348 |
| D12 | 5 | 12 | 15 | 8 | 20 | 356 |
| D13 | 3 | 11 | 6 | 8 | 16 | 17 |
| D14 | 5 | 14 | 315 | 27 | 22 | 347 |
| D15 | 1 | 2 | 12 | 1 | 2 | 13 |
| D16 | 1 | 1 | 1 | 1 | 3 | 1 |
| D17 | 5 | 1 | 19 | 5 | 21 | 359 |
| D18 | 2 | 1 | 9 | 2 | 20 | 348 |
| D19 | 5 | 2 | 23 | 5 | 20 | 365 |
| D20 | 5 | 2 | 2 | 5 | 20 | 348 |
| D21 | 2 | 2 | 1 | 2 | 19 | 342 |
| D22 | 2 | 2 | 1 | 2 | 19 | 342 |
| D23 | 0 | 1 | 5 | 2 | 14 | 17 |
| D24 | 0 | 1 | 1 | 0 | 1 | 1 |
| D25 | 0 | 1 | 4 | 2 | 14 | 4 |
| D26 | 0 | 2 | 1 | 0 | 2 | 1 |
| D27 | 0 | 1 | 1 | 0 | 1 | 1 |
| D28 | 0 | 1 | 2 | 0 | 1 | 2 |
| D29 | 0 | 1 | 1 | 0 | 1 | 1 |
| D30 | 0 | 1 | 1 | 0 | 1 | 1 |
| D31 | 0 | 2 | 1 | 0 | 2 | 1 |
| D32 | 0 | 2 | 1 | 0 | 2 | 1 |
| D33 | 0 | 1 | 5 | 0 | 1 | 5 |
| D34 | 0 | 0 | 1 | 0 | 0 | 1 |
Literature verification of predicted direct compound-cardiovascular disease interactions
| Predicted interactions | Validated literatures |
|---|---|
| Borneol (C8)—Hyperlipidemia (D16) | Borneol has ameliorative effect of hyperlipidemia in diabetic Wistar rats [ |
| Cryptotanshinone (C10)—Diabetes mellitus type 2 (D20) | Cryptotanshinone has effect of antidiabetes via activation of AMP-activated protein kinase [ |
| Ginsenoside-Rg1 (C18)—Diabetes mellitus type 2 (D20) | Ginsenoside-Rg1 can alleviate the insulin resistance through increasing the uptake of glucose and decreasing the output of glucose [ |
| Tanshinone IIA (C40)—Diabetes mellitus type 2 (D20) | Tanshinone IIA may alleviate type 2 DM symptoms in experimental rats [ |
| Cryptotanshinone (C10)—Obesity (D12) | Cryptotanshinone promotes commitment to the brown adipocyte lineage and mitochondrial biogenesis in C3H10T1/2 mesenchymal stem cells to alleviate obesity [ |
| Tanshinone IIA (C40)—Obesity (D12) | Tanshinone IIA may treat obesity through PPARγ [ |
| Tanshinone IIA (C40)—Angina pectoris (D18) | Sodium tanshinone IIA silate can act as an add-on therapy in patients with unstable angina pectoris [ |
| Ginsenoside-Rg1 (C18)—Acute Myocardial infarction (D1) | Ginsenoside-Rg1 could enhance angiogenesis and ameliorates ventricular remodeling in a rat model of Acute Myocardial infarction [ |
Fig. 3D23 centered modules generated from expanded (a) and original (b) network
Fig. 4D13 centered modules generated from original (a) and expanded (b) network
Fig. 5D25 centered modules generated from original (a) and expanded (b) network
Fig. 6The important modules identified from expanded (a) and original (b) network